Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole

2011 ◽  
Vol 132 (2) ◽  
pp. 625-629 ◽  
Author(s):  
Shalini Singh ◽  
Jack Cuzick ◽  
David Mesher ◽  
Bill Richmond ◽  
Anthony Howell
Keyword(s):  
Vitamin D ◽  
Aromatase Inhibitors ◽  
Serum Vitamin ◽  
Musculoskeletal Symptoms ◽  
Baseline Serum ◽  
Serum Vitamin D ◽  
Vitamin D Levels

Association Between cardiometabolic risk factor and responsiveness to vitamin D supplementation: A New Approach using Artificial Neural Network analysis

2020 ◽  
Author(s):  
Elahe Allahyari ◽  
Parichehr Hanachi ◽  
Seyed Jamal Mirmoosavi ◽  
Gordon A. Ferns ◽  
Afsane Bahrami ◽  
...  
Keyword(s):  
Vitamin D ◽  
Risk Factor ◽  
Cardiometabolic Risk ◽  
Serum Vitamin ◽  
Vitamin D Supplementation ◽  
Cardiometabolic Risk Factor ◽  
Baseline Serum ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
Artificial Neural

Abstract BackgroundAccumulating data have highlighted the prominence of supplementation as an effective approach for vitamin D deficiency. But individuals vary in their response to vitamin D supplementation. In this study, the effect of cardiometabolic risk factors were evaluate on magnitude of response to vitamin D supplementation by using novel statistical analysis, artificial neural networks(ANNs).Methods608 participants aged between 12 to 19 years old were assed in this prospective interventional study. Nine vitamin D capsules containing 50000IU vitamin D/weekly were given to all participants over the 9 week period. The change in serum 25(OH)D level was calculated as the difference between post-supplementation and basal levels. Suitable ANNs model were selected between different algorithms in the hidden and output layers and different numbers of neurons in the hidden layer. Then, the major determinants in predicting response to vitamin D supplementations were identified (Trial registration: IRCT201509047117N7; 2015-11-25; Retrospectively registered)ResultsSigmoid in both hidden and output layers with 4 hidden neurons had acceptable sensitivity, specificity and accuracy area under the ROC curve in our study. Baseline serum vitamin D (30.4%), waist to hip ratio (10.5%), BMI (10.5%), systolic blood pressure (8%), heart rate (6.4%), and waist circumference (6.1%) were the greatest importance in predicting the response in serum vitamin D levels. ConclusionWe provide the first attempt to relate anthropometric specific recommendations to attain serum vitamin D targets. With the exception of cardiometabolic risk factor, the relative importance of other factors and the mechanisms by which these factors may affect the response requires further analysis in future studies.

scholarly journals Evaluation of efficacy of a nanoparticle based vitamin D formulation in correction of vitamin D levels in patients with documented deficiency or insufficiency of vitamin D

2017 ◽  
Vol 3 (3) ◽  
pp. 486
Author(s):  
Kishore A. Manek
Keyword(s):  
Vitamin D ◽  
Serum Vitamin ◽  
Vitamin D Supplementation ◽  
Open Label ◽  
Baseline Serum ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
Post Marketing ◽  
Sufficient Vitamin ◽  
To Receive

<p><strong>Background:</strong> In India more than 90% of apparently healthy Indians have subnormal 25(OH) D levels. To maintain sufficient vitamin D level, apart from sunlight and food containing vitamin D, supplementation with vitamin D is also required. The objective of this study was to find out effectiveness of nanoparticle based vitamin D formulations in patient of vitamin D deficiency and insufficiency</p><p><strong>Methods:</strong> This was a prospective, open label, single arm, non-comparative, dose response post-marketing efficacy study (PMS) – phase-4 study to find the effectiveness of a nanoparticle based vitamin D formulation in adult patients between 18 to 65 years of either gender, attending/visiting the study site with documented deficiency or insufficiency of vitamin D (&lt;30 ng/ml) or sign and symptoms of deficiency or insufficiency of vitamin D. Each subject planned to receive 60,000 IU of nanoparticle based vitamin D, once weekly, for 8 weeks orally. Serum 25(OH) D levels were measured at baseline, 4 and 8 week.</p><p><strong>Results:</strong> The mean baseline serum 25[OH] D levels were 15.90. After treatment with nanoparticle based vitamin D there was a significant increase in the serum vitamin D levels at 4 weeks (41.03) and 8 weeks (31.38) (p&lt;0.0001). Patients who have received treatment for at least 4 weeks’ period (n=38), the improvement (serum 25[OH] D &gt;30 ng/ml) was seen in 84.2% patients (n=32) at the end of 4 weeks itself. There is significant increased (&lt;0.0001) in the physical component scores of the SF-12 QOL questionnaire after 8 weeks of therapy.</p><p><strong>Conclusions:</strong> Nanoparticle based formulation of vitamin D<sub>3</sub> is effective and safe in correction of vitamin D levels in patients with documented deficiency or insufficiency of vitamin D. Also the safety and tolerability is well accepted and reported good to excellent by patients and physician.</p><p> </p>

Abstract P010: Serum Vitamin D and Risk of Heart Failure: Prospective Results From the Moli-sani Study

Circulation ◽  
2016 ◽  
Vol 133 (suppl_1) ◽  
Author(s):  
Simona Costanzo ◽  
Amalia De Curtis ◽  
Augusto Di Castelnuovo ◽  
Mariarosaria Persichillo ◽  
Maria B Donati ◽  
...  
Keyword(s):  
Heart Failure ◽  
Vitamin D ◽  
Multivariable Analysis ◽  
Serum Vitamin ◽  
C Reactive Protein ◽  
Baseline Serum ◽  
Serum Vitamin D ◽  
Reactive Protein ◽  
Vitamin D Levels ◽  
Incident Cases

Introduction: Vitamin D deficiency has been associated with the progression of heart failure (HF) and Vitamin D supplementation may have protective effects in patients with HF. However, little is known on the predictive value of circulating Vitamin D levels on HF risk. Hypothesis: Low serum Vitamin D levels are associated with incident HF in a large prospective cohort of Italian adults. Methods: We analyzed 18,689 (48.4% men, age ≥35 years) HF-free individuals randomly recruited from the general population of the Moli-sani study, for whom complete data on HF and serum Vitamin D were available. Vitamin D was measured on serum by an immunoassay in the central laboratory of European BiomarCaRE project (Abbott Architect 25-OH Vitamin D, Wiesbaden, Germany). The cohort was followed up for a median of 4.2 years (80,849 person-years). Baseline serum Vitamin D was categorized in deficient/insufficient, hypovitaminosis, and normal (Table). Incident cases of HF were identified by linkage with the regional archive of hospital discharges. Hazard ratios (HRs) were calculated using Cox-proportional hazard models. Results: Subjects with normal, hypo or insufficient levels of Vitamin D were 12.2%, 79.6% and 8.2%, respectively. We identified 412 incident cases of HF. The incidence of HF was 1.1%, 2.2% and 3.9%, respectively in subjects with normal, hypo and insufficient levels of Vitamin D. After a multivariable analysis, considering a large panel of potential covariates, individuals with deficient/insufficient levels of serum Vitamin D showed a higher risk of developing HF (HR: 1.78, 95% CI: 1.07-2.97) than those with normal levels. Further adjustment for C-Reactive Protein did not modify the association (Table). Conclusions: Deficiency of Vitamin D is associated with a significantly higher risk of HF in a general adult population. This association was not explained by an inflammatory marker such as C-Reactive Protein.

scholarly journals The Role of Vitamin D in Diabetes and Cardiovascular Disease: An Updated Review of the Literature

2015 ◽  
Vol 2015 ◽  
pp. 1-15 ◽  
Author(s):  
Dimitrios Papandreou ◽  
Zujaja-Tul-Noor Hamid
Keyword(s):  
Vitamin D ◽  
Cardiovascular Diseases ◽  
Large Scale ◽  
Serum Vitamin ◽  
Strong Relationship ◽  
Baseline Serum ◽  
Vitamin D Receptors ◽  
Serum Vitamin D ◽  
Body Tissues ◽  
Vitamin D Levels

The dietary reference values for Vitamin D were set primarily considering its role in bone health, but with the discovery of Vitamin D receptors throughout body tissues, new links with other health conditions are now studied, such as for diabetes and cardiovascular diseases (CVD). This paper shall analyze and examine all new research studies carried out, especially in 2013–2015 regarding diabetes mellitus (DM) and cardiovascular diseases (CVD). Vast research has been carried out to establish strong relationship between Vitamin D serum levels, supplementation, diabetes, and CVD. However, the results from researches identified in this paper are disputable. Benefits of Vitamin D adequate levels were recognized from gestational period until later in disease development such as diabetes and/or CVD, but since not all studies are in agreement further investigation is suggested. Researches conducting large randomized controlled trials, exploring range of supplement doses, with variable baseline serum Vitamin D levels, and inclusion of array of associated parameters, are still required to conduct large-scale analysis and draw conclusion as a risk factor. Until then it is possible to conclude that maintenance of serum Vitamin D levels holds advantageous aspects in diabetic and cardiovascular conditions, and people should strive to attain them.

scholarly journals Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies

2015 ◽  
Vol 33 (13) ◽  
pp. 1482-1490 ◽  
Author(s):  
Jennifer L. Kelly ◽  
Gilles Salles ◽  
Bryan Goldman ◽  
Richard I. Fisher ◽  
Pauline Brice ◽  
...  
Keyword(s):  
Vitamin D ◽  
Overall Survival ◽  
Follicular Lymphoma ◽  
Serum Vitamin ◽  
Baseline Serum ◽  
Serum Vitamin D ◽  
Hazard Ratios ◽  
Vitamin D Levels ◽  
The Impact

Purpose Recent literature reports a potential association between high vitamin D and improved lymphoma prognosis. We evaluated the impact of pretreatment vitamin D on follicular lymphoma (FL) outcome. Patients and Methods SWOG participants were previously untreated patients with FL enrolled onto SWOG clinical trials (S9800, S9911, or S0016) involving CHOP chemotherapy plus an anti-CD20 antibody (rituximab or iodine-131 tositumomab) between 1998 and 2008. Participants included in our second independent cohort were also previously untreated patients with FL enrolled onto the Lymphoma Study Association (LYSA) PRIMA trial of rituximab plus chemotherapy (randomly assigned to rituximab maintenance v observation) between 2004 and 2007. Using the gold-standard liquid chromatography–tandem mass spectrometry method, 25-hydroxyvitamin D was measured in stored baseline serum samples. The primary end point was progression-free survival (PFS). Results After a median follow-up of 5.4 years, the adjusted PFS and overall survival hazard ratios for the SWOG cohort were 1.97 (95% CI, 1.10 to 3.53) and 4.16 (95% CI, 1.66 to 10.44), respectively, for those who were vitamin D deficient (< 20 ng/mL; 15% of cohort). After a median follow-up of 6.6 years, the adjusted PFS and overall survival hazard ratios for the LYSA cohort were 1.50 (95% CI, 0.93 to 2.42) and 1.92 (95% CI, 0.72 to 5.13), respectively, for those who were vitamin D deficient (< 10 ng/mL; 25% of cohort). Conclusion Although statistical significance was not reached in the LYSA cohort, the consistent estimates of association between low vitamin D levels and FL outcomes in two independent cohorts suggests that serum vitamin D might be the first potentially modifiable factor to be associated with FL survival. Further investigation is needed to determine the effects of vitamin D supplementation in this clinical setting.

Association between musculoskeletal symptoms and serum vitamin D levels in women receiving aromatase inhibitor treatment.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e20560-e20560
Author(s):  
Alice C. Shapiro ◽  
Karen K Swenson ◽  
MaryJo Nissen ◽  
Susan Adlis ◽  
Laura Maybon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Linear Regression Analysis ◽  
Joint Stiffness ◽  
Serum Vitamin ◽  
Vitamin D Insufficiency ◽  
Musculoskeletal Symptoms ◽  
Hand Osteoarthritis ◽  
Serum Vitamin D ◽  
Vitamin D Levels

e20560 Background: Up to 40% of women with estrogen positive (ER+) breast cancer treated with aromatase inhibitors (AIs) experience musculoskeletal symptoms (AIMSS) such as bone pain, joint pain, joint stiffness, and muscle weakness that negatively impact functional ability. Previous reports indicate that vitamin D insufficiency is common in this patient population and that D supplementation might attenuate AIMSS by affecting muscle, bone and/or nerve metabolism. To test the association between AIMSS and serum 25(OH)D levels, we analyzed data collected as part of a pilot prospective study assessing instrument effect sizes to measure AIMSS. Methods: Data were analyzed from 58 women, age 61 ± 10 y with a history of ER+ breast cancer stage I-IIIa. AIMSS symptoms were measured at baseline (pre AI) and 6 mo using the Breast Cancer Prevention Trial Musculoskeletal Subscale (BCPT-MS), the Western Ontario and McMaster Universities Arthritis Index (WOMAC), and the Australian-Canadian Hand Osteoarthritis Index (AUSCAN). Serum 25(OH)D was measured by radioimmunoassay (Diasorin liaison, Stillwater, MN). Linear regression analysis was used to determine the association between changes in AIMSS scores (dependent variables) and changes in serum 25(OH)D from baseline to 6 mo, adjusting for age and season. Results: From baseline to 6 mo there were significant increases on all AIMSS measures (BCPT-MS, WOMAC and AUSCAN p<0.02). These increases in AIMSS measures were not associated with the change in serum 25(OH)D from baseline to 6 mo (Δ =11 ng/ml ± 12; p<0.001). Conclusions: Worsening of symptoms during the initial 6 months of AI therapy was not associated with changes in serum 25(OH)D levels. These results suggest that short-term supplementation with 25(OH)D does not attenuate the symptoms of AIMSS in post-menopausal women with ER+ breast cancer during the first 6 mo of AI therapy. However vitamin D insufficiency was uncommon in this study population (mean 25(OH)D at baseline 31 ng/ml ± 10 and 42± 13 ng/ml at 6 mo). Well controlled clinical trials are needed to further our understanding of these relationships. Clinical trial information: NCT01074320.

scholarly journals Vitamin D in Critically Ill Patients - From Molecular Damage Interactions to Clinical Outcomes Benefits. When, Why, How?

2018 ◽  
Vol 1 (1) ◽  
pp. 59-66 ◽  
Author(s):  
Alida Moise
Keyword(s):  
Vitamin D ◽  
Cognitive Impairment ◽  
Regulation Of Gene Expression ◽  
Serum Vitamin ◽  
Vitamin D Supplementation ◽  
Multiple Roles ◽  
Transcriptional Level ◽  
Baseline Serum ◽  
Serum Vitamin D ◽  
Vitamin D Levels

Abstract Vitamin D - „the sunshine vitamin” is essential for the good functioning of the human body. The most important forms of the vitamin D are the vitamin D2 and the vitamin D3, both biologically inactived. Vitamin D can come from: diet or nutritiv suplimentts and skin. The activation of vitamin D is effect in two steps to the physiologically active 1,25-dihydroxyvitamin D [1,25(OH)2D]. The biological actions of Vitamin D involve regulation of gene expression at the transcriptional level and are mediated through binding to a Vitamin D Receptor (VDR). Vitamin D has multiple roles: hormonale/ nonhormonale, skeletale/nonscheletale, genomice/nongenomice. Interesting is inversely corelation between Vitamin D and total body fat (BMI) and correlation between Vitamin D and cognitive impairment, especially Alzheimer Disease or delirium during hospitalisation. The curent recomandations regarding the supplying with Vitamin D are different for regions of the globe, also differ depending on the baseline serum Vitamin D and on the desired effect. So, potential nonskeletal effects occur at levels >30ng/ml, above 50-75ng/ml, serum level who should become the target of the supplementation. The loading dose should be considered perioperatively for rapid effects. In conclusion, Vitamin D is more than just a vitamin. It is a substance with multiple roles in body’s economy, and in recent years there has been an interest in the relation be tween vitamin D deficiency and obesity or cognitive impairment. The majority of the data supports association, not causation, of low vitamin D levels. In other words, much of data does not clearly support the idea that vitamin D supplementation in a patient with low vitamin D levels reduces the risk of these diseases. But, the supplimentation is very easy and no harm might be done.

scholarly journals Association between Cardiometabolic risk factor and responsiveness to vitamin D supplementation: a new approach using artificial neural network analysis

BMC Nutrition ◽  
2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Elahe Allahyari ◽  
Parichehr Hanachi ◽  
Seyed Jamal Mirmoosavi ◽  
Gordon A.Ferns ◽  
Afsane Bahrami ◽  
...  
Keyword(s):  
Risk Factors ◽  
Vitamin D ◽  
Cardiometabolic Risk ◽  
Serum Vitamin ◽  
Vitamin D Supplementation ◽  
Cardiometabolic Risk Factors ◽  
Baseline Serum ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
Artificial Neural

Abstract Background There are increasing data highlighting the effectiveness of vitamin D supplementation in the treatment of vitamin D deficiency. But individuals vary in their responsiveness to vitamin D supplementation. In this study, the association between several cardiometabolic risk factors and the magnitude of response to vitamin D supplementation (change in vitamin D level) was investigated using a novel artificial neural networks (ANNs) approach. Methods Six hundred eight participants aged between 12 to 19 years old were recruited to this prospective interventional study. Nine vitamin D capsules containing 50,000 IU vitamin D/weekly were given to all participants over the 9 week period. The change in serum 25(OH) D level was calculated as the difference between post-supplementation and basal levels. Suitable ANNs model were selected between different algorithms in the hidden and output layers and different numbers of neurons in the hidden layer. The major determinants for predicting the response to vitamin D supplementation were identified. Results The sigmoid in both the hidden and output layers with 4 hidden neurons had acceptable sensitivity, specificity and accuracy, assessed as the area under the ROC curve, was determined in our study. Baseline serum vitamin D (30.4%), waist to hip ratio (10.5%), BMI (10.5%), systolic blood pressure (8%), heart rate (6.4%), and waist circumference (6.1%) were the most important factors in predicting the response to serum vitamin D levels. Conclusion We provide the first attempt to relate anthropometric specific recommendations to attain serum vitamin D targets. With the exception of cardiometabolic risk factors, the relative importance of other factors and the mechanisms by which these factors may affect the response requires further analysis in future studies (Trial registration: IRCT201509047117N7; 2015-11-25; Retrospectively registered).

Clinical factors correlated with vitamin D deficiency in patients with obesity scheduled for bariatric surgery: A single center experience

2020 ◽  
Vol 90 (3-4) ◽  
pp. 346-352
Author(s):  
Vincenzo Pilone ◽  
Salvatore Tramontano ◽  
Carmen Cutolo ◽  
Federica Marchese ◽  
Antonio Maria Pagano ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Serum Vitamin ◽  
Inverse Correlation ◽  
Model Assessment ◽  
Cross Sectional ◽  
Serum Vitamin D ◽  
Female Sex ◽  
Vitamin D Levels

Abstract. We aim to assess the prevalence of vitamin D deficiency (VDD) in patients scheduled for bariatric surgery (BS), and to identify factors that might be associated with VDD. We conducted a cross-sectional observational study involving all consecutive patients scheduled for BS from 2017 to 2019. The exclusion criteria were missing data for vitamin D levels, intake of vitamin D supplements in the 3 months prior to serum vitamin D determination, and renal insufficiency. A total of 206 patients (mean age and body mass index [BMI] of 34.9 ± 10.7 years, and 44.3 ± 6.99 kg/m2, respectively) met the inclusion criteria and were enrolled for data analysis. VDD (<19.9 ng/mL), severe VDD (<10 ng/mL), and vitamin D insufficiency (20–29.9 ng/mL) were present in 68.8 %, 12.5 %, and 31.2 % of patients, respectively. A significant inverse correlation was found between vitamin D levels and initial BMI, parathyroid hormone, and homeostatic model assessment of insulin resistance (r = −0.280, p < 0.05; r = −0.407, p = 0.038; r = −0.445, p = 0.005), respectively. VDD was significantly more prevalent in patients with higher BMI [−0.413 ± 0.12, CI95 % (−0.659; −0.167), p = 0.006], whereas no significant association between hypertension [−1.005 ± 1.65, CI95 % (−4.338; 2.326), p = 0.001], and diabetes type 2 (T2D) [−0.44 ± 2.20, CI95 % (−4.876; 3.986), p = 0.841] was found. We observed significant association between female sex and levels of vitamin D [6.69 ± 2.31, CI95 % (2.06; 11.33), p = 0.006]. The present study shows that in patients scheduled for BS, VDD deficiency is common and was associated with higher BMI, and female sex.

Sign in / Sign up

Export Citation Format

Share Document